2014.9－2018.6 华中科技大学协和医院，博士学位

1999.9－2002.6 华中科技大学药理学系，硕士学位

1991.9－1996.6 同济医科大学临床医学系，学士学位

2002.7－至今 华中科技大学同济医学院附属协和医院药学部，药师、主管药师、副主任药师、主任药师 2007.2－2008.2 德国Dr. Margarete Fischer-Bosch临床药理研究所，国家公派访问学者 2014.7－2015.10 清华大学医院药事创新管理高级研修班（第八期）培训 1996.7－1999.8 华中科技大学同济医学院临床药理研究所

1. 主持国家自然科学基金面上项目“代谢-转运互作”介导槲皮素及其活性代谢物Q3GA调控CsA药动学的分子机制（No. 81874326，2019.1~2022.12）；

2. 主持国家自然科学基金面上项目“肾移植受者嘌呤类药物不良反应缘由：NDPK/TGTP/Rac1代谢通路关键基因变异相关研究” （No. 81273591，2013.1 ~ 2016.12）；

3. 参与国家自然科学基金面上项目，肾移植患者中环孢素导致肝损伤的个体差异及其机制研究（No. 81573506，2016.1-2019.12；排名第2）；

4. 参与国家重点研发计划精准医学研究重点专项课题“典型病种精准用药模型的集成、推广与优化”（No. 2017YFC0909904，2017/07-2020/12，822万，排名第2）；

5. 主持华中科技大学自主创新研究基金（重点专项项目）“转运体-代谢酶交互作用建模及对CNIs-银杏药动学的影响”（No. 2014YGYL003，2014.4~2015.12）；

6. 主持湖北省自然科学基金项目“NDPK基因型对嘌呤类药物反应的影响”（No. 2009CDB380，2009.12 ~ 2011.12）；

7. 主持华中科技大学自主创新研究基金“NDPK 活性和基因变异与嘌呤类药物不良反应相关性研究”（No. 2011JC039，202011.6~2012.12）；

8. 参与国家自然科学基金面上项目“随机环境下的药动学-药效学建模及其在白藜芦醇抗肿瘤多靶点效应中的研究”（No. 30973586，2010.1 ~ 2012.12）；

9. 参与国家自然科学基金面上项目“蝙蝠葛碱和蝙蝠葛苏林碱对获得性长QT综合征的细胞和离子机制”（No. 30572346，2006.1 ~ 2008.12）；

10. 作为主要研究者（PI）主持并完成化学药品1.1类新药：羟尼酮胶囊、吡非尼酮胶囊、艾瑞昔布，治疗用生物制品1类新药：注射用重组人甲状旁腺素（1-84）和重组人红细胞生成素（Fc）融合蛋白注射液，重组人甲状旁腺素（1-34），头孢呋辛酯、奥美拉唑碳酸氢钠、艾塞那肽，比阿培南等30余项新药Ⅰ期临床试验。

1. Yang T, Liu Y, Huang X, Zhang R, Yang C, Zhou J, Zhang Y, Wan J, Shi S*. Quercetin 3 O β D glucoside decreases the bioavailability of cyclosporin A through regulation of drug metabolizing enzymes, transporters and nuclear receptors in rats. Mol Med Rep. 2018;18(3):2599-2612.

2. Huang Y, Hu K, Zhang S, Dong X, Yin Z, Meng R, Zhao Y, Dai X, Zhang T, Yang K, Liu L, Huang K, Shi S, Zhang Y, Chen J, Wu G, Xu S. S6K1 phosphorylation-dependent degradation of Mxi1 by β-Trcp ubiquitin ligase promotes Myc activation and radioresistance in lung cancer. Theranostics. 2018; 8(5): 1286-1300.

3. Xie J, Li Y, Jiang K, Hu K, Zhang S, Dong X, Dai X, Liu L, Zhang T, Yang K, Huang K, Chen J, Shi S, Zhang Y, Wu G, Xu S. CDK16 phosphorylates and degrades p53 to promote radioresistance and predicts prognosis in lung cancer. Theranostics. 2018;8(3):650-662.

4. Liu Y, Wu J, Li Z, Luo Y, Zeng F, Shi S*. Tolerability and pharmacokinetics of hydronidone, an antifibrotic agent for hepatic fibrosis, after single and multiple doses in healthy subjects: an open-label, randomized, dose-escalating, first-in-human study. Eur J Drug Metab Pharmacokinet. 2017;42(1):37-48

5. Liu Y, Zhou J, Luo X, Yang C, Zhang Y, Shi S*. Association of RAC1 gene polymorphisms with primary end-stage renal disease in Chinese renal recipients. PLoS One. 2016;11(2):e0148270.

6. Zhou J, Liu Y, Luo X, Shen R, Yang C, Yang T, Shi S*. Identification and association of RAC1 gene polymorphisms with mRNA and protein expression levels of Rac1 in solid organ (kidney, liver, heart) transplant recipients. Mol Med Rep. 2016;14(2): 1379-1388.

7. Xiaomei Luo, Tingyu Yang, Chunxiao Yang, Jiali Zhou, Yani Liu, Yifei Huang, Shaojun Shi*. Effects of multiple oral dosing of cyclosporine on the pharmacokinetics of quercetin in rats. Int J Clin Exp Med. 2016;9(3):5880-5890.

8. Liu Y, Luo X, Yang C, Yang T, Zhou J, Shi S*. Impact of quercetin induced changes in drug metabolizing enzyme and transporter expression on the pharmacokinetics of cyclosporine in rats. Mol Med Rep. 2016;14(4):3073-3085.

9. Rufei Shen, Chunxiao Yang, Xiaomei Luo, Tingyu Yang, Jiali Zhou, Yani Liu, Shaojun Shi*. Enzyme kinetics studies of nucleoside diphosphate kinase in human erythrocytes and frequency distribution in healthy subjects and transplant recipients in Chinese Han population. Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences. 2015; 4(3):93-103.

10. Shi S, Li Y. Interplay of drug-metabolizing enzymes and transporters in drug absorption and disposition. Curr Drug Metab. 2014;15(10):915-941.

11. Shi S. Biologics: an update and challenge of their pharmacokinetics. Curr Drug Metab. 2014;15(3):271-290.

12. Liu Y, Yang C, Li Z, Zhou J, Lv Y, Zhang Y, Zeng F, Shi S*. Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects. Clin Ther. 2014; 36(6):940-952.

13. Li Y, Hu Y, Shi S*, Jiang L. Evaluation of antioxidant and immuno-enhancing activities of Purslane polysaccharides in gastric cancer rats. Int J Biol Macromol. 2014;68:113-116.

14. Liu Y, Li Z, Yang C, Zheng H, Lv Y, Chen H, Zhang Y, Shi S*. Tolerability and pharmacokinetics of biapenem following single and multiple intravenous administrations in healthy Chinese subjects: an open-label, randomized, single-center study. Drug Res (Stuttg). 2013;63(8):396-403.

15. Shi S, Klotz U. Drug interactions with herbal medicines. Clin Pharmacokinet. 2012;51(2):77-104.

16. Shi S, Liu Y, Li Z, Wu J, Zhou X, Zeng F. Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. Arzneimittelforschung. 2012;62(2):75-82.

17. Liu Y, Shi S*, Wu J, Li Z, Zhou X, Zeng F. Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone [rhPTH(1-84)] after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. Basic Clin Pharmacol Toxicol. 2012;110(2):154-161.

18. Liu Y, Huang J, Liu J, Ma L, Lv Y, Shi S*. A simple and sensitive liquid chromatographic technique for the determination of cefotetan disodium in human plasma and its application in a pharmacokinetic study. J Huazhong Univ Sci Technolog Med Sci. 2012;32(5):779-784.

19. Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12(7):601-610.

20. Karner S, Shi S*, Fischer C, Schaeffeler E, Neurath MF, Herrlinger KR, Hofmann U, Schwab M. Determination of 6-thioguanosine diphosphate and triphosphate and nucleoside diphosphate kinase activity in erythrocytes: novel targets for thiopurine therapy? Ther Drug Monit. 2010;32(2):119-128.

21. Shi S, Liu Y, Li Z, Zheng H, Lv Y, Chen H. Pharmacokinetics and tolerability of intravenous cefotetan disodium for injection in healthy Chinese volunteers: A randomized, open-label, single- and multiple-dose study. Clin Ther. 2010;32(10):1832-1841.

22. Shi S, Liu Y, Wu J, Li Z, Zhao Y, Zhong D, Zeng F. Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. Clin Ther. 2010;32(11):1977-1986.

23. Shi Shaojun, Wu Jianhong, Wu Jun, Zeng Fandian. Development and validation of an improved HPLC method for the simultaneous determination of pirfenidone and its carboxylic acid metabolite in human plasma. Chromatographia. 2009; 69:459-463.

24. Birkenfeld AL, Jordan J, Hofmann U, Busjahn A, Franke G, Krüger N, Igel S, Mürdter T, Drescher S, Shi S, Engeli S, Schwab M, Eichelbaum M, Luft FC, Fromm MF. Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins. Clin Pharmacol Ther. 2009;86(6):605-608.

25. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64(10):935-951.

26. Shi S, Mörike K, Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol. 2008;64(2):183-199.

27. Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol. 2008;64(3):233-252.

28. Shi S, Wu J, Chen H, Chen H, Wu J, Zeng F. Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol. 2007;47(10):1268-1276.